MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
Rhea-AI Summary
MiNK Therapeutics (NASDAQ: INKT) announced an abstract acceptance for presentation at the American Thoracic Society (ATS) 2026 International Conference in Orlando, May 15-20, 2026. The abstract describes a combination of N-803 and investigational agenT-797 for unresolving Coccidioides immitis infection.
Presenter Terese Hammond, MD, will present Poster Board #103 in Session D107 on Wednesday, May 20, 2026, 11:00 AM–1:00 PM EDT. In line with ATS rules, no data or results are disclosed until the conference presentation.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – INKT
On the day this news was published, INKT gained 0.38%, reflecting a mild positive market reaction. This price movement added approximately $209K to the company's valuation, bringing the market cap to $55.25M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Scanner data does not flag a coordinated sector move. Several cell therapy peers show gains (e.g., ARTV +16.79%, PRLD +8.92%, ACET +8.79%, ALXO +3.89%), while INKT’s move has been minimal, suggesting news-specific rather than sector-driven dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Earnings & pipeline | Positive | +0.1% | Q4/FY25 results, cash update, and advancing Phase 2 ARDS and GVHD programs. |
| Mar 17 | Earnings date set | Positive | +4.9% | Announcement of earnings date plus iNKT platform expansion and collaboration plans. |
| Mar 10 | New collaboration | Positive | +29.3% | Strategic C-Further partnership on PRAME-targeted TCR-engineered iNKT therapy. |
| Mar 10 | Partner program launch | Positive | +29.3% | C-Further launches pediatric oncology programs including MiNK-partnered PRAME iNKT therapy. |
| Feb 03 | Conference data | Positive | +2.2% | Keystone data on allo-iNKT therapy in IPF supporting disease-modifying potential. |
Recent stock reactions have consistently aligned with positive catalysts, with all 5 tracked events showing positive price responses to constructive operational or clinical updates.
Over the past few months, MiNK reported Q4 and full-year 2025 results with $13.4M year-end cash and additional $3.0M raised, advanced Phase 2 programs, and expanded its iNKT platform via a PRAME-targeted pediatric cancer collaboration backed by up to ~$1.1M in non-dilutive funding. Conference data in lung disease and repeated positive price reactions to clinical and partnership news frame this ATS abstract acceptance as part of an ongoing scientific visibility push.
Regulatory & Risk Context
An effective S-3 shelf filed on Nov 7, 2025 permits up to $150,000,000 in securities, including an ATM program for up to $50,000,000 of common stock. Under General Instruction I.B.6, current ATM capacity is limited to $6,641,284, with sales agent fees of 3.0% of gross proceeds.
Market Pulse Summary
This announcement centers on acceptance of an agenT-797 abstract for ATS 2026, adding to recent scientific and clinical visibility for MiNK’s iNKT platform. In the past six months, the company has highlighted Phase 2 progress, non-dilutive funding of up to ~$1.1M, and collaborations in pediatric oncology. Investors may watch for data quality at the conference, subsequent trial updates, and any utilization of the up to $150,000,000 shelf and related ATM program.
Key Terms
allogeneic medical
invariant natural killer T medical
allo-iNKT medical
interleukin-15 superagonist medical
immunotherapy medical
coccidioides immitis medical
AI-generated analysis. Not financial advice.
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the ATS International Conference 2026 occurring May 15-20, 2026 in Orlando, Florida.
The abstract, titled “Novel Interleukin-15 Superagonist (N-803) and Invariant Natural Killer T Cell (agenT-797) Combination Immunotherapy for Unresolving Coccidioides immitis Infection,” highlights a novel combination approach leveraging immune activation and restoration in severe and persistent infections.
Presentation Details
- Presenter: Terese Hammond, MD
- Poster Board: #103
- Session Title: D107- Zebras of the Lung: Rare Infections, Immune Extremes, and Diagnostic Plot Twists
- Date/Time: Wednesday, May 20, 2026 | 11:00 AM – 1:00 PM (EDT)
In accordance with American Thoracic Society guidelines, no data or results are being disclosed at this time. Full details will be presented at the conference.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK’s proprietary platform is designed to restore immune balance and drive cytotoxic responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK’s lead candidate, agenT-797, is an off-the-shelf iNKT cell therapy currently in clinical development for GvHD, solid tumors, and severe pulmonary inflammation. With a scalable cryopreserved manufacturing process and differentiated biology bridging innate and adaptive immunity, MiNK is committed to developing next-generation immune reconstitution therapies. For more information, visit www.minktherapeutics.com or follow us on X @MiNK_iNKT.
About AgenT-797
AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy that harnesses the dual power of innate and adaptive immunity. iNKTs function as “master regulators,” combining the cytotoxic capabilities of NK cells with T-cell–like antigen recognition and memory. This unique biology enables a robust, pathogen-agnostic immune response that can be directed against hard-to-treat tumors. Manufactured by MiNK Therapeutics in Lexington, MA, agenT-797 is a scalable, off-the-shelf product designed to provide accessible, transformative treatment options. In clinical trials, agenT-797 can bolster peripheral memory T-cell activation, enhance tumor infiltration, and potentially improve outcomes for patients with solid cancers (Cytryn et al. AACR IO 2024, Oncogene. 2024) and to combat inflammation in critically ill patients with severe respiratory pathology (Nature Communications. 2024).
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, safety, and anticipated benefits of agenT-797; clinical trial design, timing, and enrollment; and MiNK’s broader development plans. These statements are subject to risks and uncertainties detailed in MiNK’s most recent filings with the Securities and Exchange Commission. MiNK cautions investors not to place undue reliance on these statements, which speak only as of the date of this release.
Contacts:
Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com
Source: MiNK Therapeutics
